SNDX vs GLUE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SNDX · Syndax Pharmaceuticals$9.54 ▲ 1.81%
GLUE · Monte Rosa Therapeutics$10.57 ▲ 3.12%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SNDX -39.3%
- GLUE -24.8%
Head to head
| Metric | SNDX | GLUE |
|---|---|---|
| Price | $9.54 | $10.57 |
| Change today | ▲ 1.81% | ▲ 3.12% |
| Market cap | $858.87M | $903.21M |
| Return, 3 months | -53.2% | -33.2% |
| Return, year to date | -54.6% | -32.6% |
| Return, 1 year | -36.6% | -14.1% |
| P/E (TTM) | – | – |
| P/B | -49.9 | 1.8 |
| P/E percentile vs own 5y | 56th | 12th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +91.8% | -61.3% |
| Net profit growth (YoY) | +31.3% | -253.0% |
| Gross margin | 95.8% | – |
| Operating margin | -77.0% | -633.0% |
| Net margin | -87.5% | -560.9% |
| Return on equity | -255.9% | -42.7% |
| Analyst target vs. price | +301.4% | +157.0% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 26 | 45 |
| 30-day volatility | 114.7% | 58.0% |
| Max drawdown, 1 year | -62.7% | -61.5% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GLUE is the largest of the group by market value.
- GLUE has returned the most over the past year.
- SNDX is growing revenue fastest.
- SNDX keeps the most profit per dollar of sales.
- GLUE has been the calmest stock over the last 30 days.